The Race to the $1,000 Genome – Daily Finance

But what happens when progress is so rapid that the law gets left behind? For biotech investors (not to mention patients), the answer is more complex -- and potentially transformative -- than it may seem at first glance. The exponential trend of ...
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *

*


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>